Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

Podobne zapisy

• T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
  od: Borch, Troels Holz, i wsp.
  Wydane: (2014)
• Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
  od: Queirolo, Paola, i wsp.
  Wydane: (2016)
• PAN-CANCER EFFICACY OF VEMURAFENIB IN BRAF(V600)-MUTANT NON-MELANOMA CANCERS
  od: Subbiah, Vivek, i wsp.
  Wydane: (2020)
• Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
  od: Nowara, Elzbieta, i wsp.
  Wydane: (2016)
• Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
  od: McArthur, Grant A, i wsp.
  Wydane: (2014)